Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

IPF in talks with BasePoint Capital over potential £490m takeover

(Sharecast News) - International Personal Finance said on Wednesday that it is in advanced talks with US specialty finance firm BasePoint Capital about a possible £490m takeover. Under the terms of the possible offer, IPF shareholders would receive 220p per share in cash and be entitled to retain the interim dividend of 3.8p per share, giving a total value of 223.8p per share.

This is a 24.9% premium to the closing share price on Tuesday.

"The board is confident in its strategy and in the company's standalone future, recognising the strong performance to date outlined in the 2025 half year results released today," said IPF.

However, the group said it has "carefully considered" the possible offer with its advisers and concluded it's at a value the board would be minded to recommend unanimously to shareholders, should a firm intention to make an offer be made.

"Accordingly, the board is in advanced discussions with BasePoint in relation to these terms and other transaction documentation, following completion of due diligence satisfactory to BasePoint," it said.

News of the takeover talks came as IPF released its results for the six months to the end of June, which showed that pre-tax profit rose 5.5% from the same period a year earlier to £49.9m, coming in ahead of company expectations.

IPF said this was driven "by excellent credit quality and good growth momentum across all our divisions".

Shore Capital analyst Gary Greenwood said: "While the shares have performed well of late and are currently trading slightly above our last published standalone fair value of 175p, the takeover premium does seem a little disappointing to us.

"The bid probably also explains why the group has not yet commenced the £15m share buyback that was proposed at the year end."

At 0940 BST, the shares were up 19% at 213p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.